MX2017011879A - Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". - Google Patents

Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".

Info

Publication number
MX2017011879A
MX2017011879A MX2017011879A MX2017011879A MX2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A
Authority
MX
Mexico
Prior art keywords
pcsk9
inhibitors
treatment
metabolism disorders
lipoprotein metabolism
Prior art date
Application number
MX2017011879A
Other languages
English (en)
Inventor
Gustafsen Camilla
Glerup Pedersen Simon
S?Ndergaard Madsen Peder
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Publication of MX2017011879A publication Critical patent/MX2017011879A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente divulgación hace referencia a inhibidores de proteína convertasa subtilisina/kexina tipo 9 (PCSK9) para el tratamiento de trastornos del metabolismo de lipoproteínas.
MX2017011879A 2015-03-20 2016-03-18 Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". MX2017011879A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201570158 2015-03-20
DKPA201570623 2015-10-02
DKPA201570839 2015-12-21
PCT/DK2016/050082 WO2016150444A1 (en) 2015-03-20 2016-03-18 Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders

Publications (1)

Publication Number Publication Date
MX2017011879A true MX2017011879A (es) 2018-04-10

Family

ID=55696811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011879A MX2017011879A (es) 2015-03-20 2016-03-18 Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".

Country Status (10)

Country Link
US (3) US10688119B2 (es)
EP (2) EP3271405A1 (es)
JP (2) JP6869894B2 (es)
KR (1) KR20170123345A (es)
CN (1) CN107531798B (es)
AU (2) AU2016235662B2 (es)
BR (1) BR112017020091A2 (es)
CA (1) CA2979756A1 (es)
MX (1) MX2017011879A (es)
WO (1) WO2016150444A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017020091A2 (pt) 2015-03-20 2018-11-06 Aarhus Universitet inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas
EP3515455B1 (en) 2016-09-20 2021-04-14 Aarhus Universitet Compounds for treatment of lipoprotein metabolism disorders
CN108753821A (zh) * 2018-06-13 2018-11-06 黄河科技学院 一种基于细胞的pcsk9抑制剂筛选方法
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3422407A1 (de) * 1984-06-16 1986-03-06 B. Braun Melsungen Ag, 3508 Melsungen Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU2753292A (en) 1991-10-04 1993-05-03 Procter & Gamble Company, The Cholesterol lowering compounds and process for making them
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
EP0628078B1 (en) 1992-12-11 1999-12-08 The Dow Chemical Company Multivalent single chain antibodies
US6255296B1 (en) * 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
US6258798B1 (en) * 1999-09-07 2001-07-10 Pharmacia Ab Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
JP4554910B2 (ja) * 2002-11-01 2010-09-29 生化学工業株式会社 血糖低下剤
EP1603543A4 (en) * 2003-02-28 2009-03-04 Florey Howard Inst THERAPEUTIC COMPOSITIONS
JP2010505432A (ja) * 2006-10-09 2010-02-25 サンタリス ファーマ アー／エス Ｐｃｓｋ９を調節するためのｒｎａアンタゴニスト化合物
WO2008118883A1 (en) * 2007-03-24 2008-10-02 Isis Pharmaceuticals, Inc. Administering antisense oligonucleotides complementary to human apolipoprotein b
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009049370A1 (en) 2007-10-16 2009-04-23 Progen Pharmaceuticals Limited Novel sulfated oligosaccharide derivatives
JP2011501952A (ja) * 2007-10-26 2011-01-20 シェーリング コーポレイション 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
ES2340902B1 (es) * 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
CN101757019B (zh) * 2008-11-10 2011-06-08 鲁南制药集团股份有限公司 用于减肥或治疗代谢综合征的药物组合物
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2011051961A1 (en) * 2009-10-01 2011-05-05 Cadila Healthcare Limited Compounds for the treatment of dyslipidemia and related diseases
WO2011053048A2 (ko) 2009-10-29 2011-05-05 연세대학교 산학협력단 신규 혈관누출 차단제
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
CA2820953A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
CN102526739B (zh) * 2010-12-27 2014-12-03 鲁南制药集团股份有限公司 治疗糖尿病的药物组合物及其应用
CN103476797A (zh) * 2011-01-28 2013-12-25 赛诺菲 包含针对pcsk9的人抗体的药物组合物
WO2012109530A1 (en) 2011-02-11 2012-08-16 Irm Llc Pcsk9 antagonists
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
EP2794661B1 (en) 2011-12-20 2019-03-06 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US20150344430A1 (en) 2012-05-25 2015-12-03 Catabasis Pharmacauticals, Iinc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
US20150190369A1 (en) 2012-07-03 2015-07-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
WO2014107739A1 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
CA2905237A1 (en) * 2013-03-15 2014-09-18 Adaerata, Limited Partnership Small molecule modulators of pcsk9 and methods of use thereof
US20160039945A1 (en) 2013-03-15 2016-02-11 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
US9480703B2 (en) * 2013-10-29 2016-11-01 Shaker A. Mousa Method and composition of glycosaminoglycans in sickle cell and vascular disorders
BR112017020091A2 (pt) 2015-03-20 2018-11-06 Aarhus Universitet inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas
EP3515455B1 (en) * 2016-09-20 2021-04-14 Aarhus Universitet Compounds for treatment of lipoprotein metabolism disorders

Also Published As

Publication number Publication date
AU2016235662B2 (en) 2020-07-30
US20180193376A1 (en) 2018-07-12
JP2021119148A (ja) 2021-08-12
JP6869894B2 (ja) 2021-05-12
EP3973958A2 (en) 2022-03-30
AU2020256388A1 (en) 2020-11-12
AU2016235662A1 (en) 2017-10-12
BR112017020091A2 (pt) 2018-11-06
CN107531798B (zh) 2022-02-18
US20220072032A1 (en) 2022-03-10
CA2979756A1 (en) 2016-09-29
US20200330504A1 (en) 2020-10-22
KR20170123345A (ko) 2017-11-07
EP3973958A3 (en) 2022-06-22
CN107531798A (zh) 2018-01-02
WO2016150444A1 (en) 2016-09-29
JP2018511596A (ja) 2018-04-26
EP3271405A1 (en) 2018-01-24
US10688119B2 (en) 2020-06-23

Similar Documents

Publication Publication Date Title
MX2023000251A (es) Composiciones para usarse en el tratamiento de un trastorno asociado a gen de proproteina convertasa subtilisina kexina (pcsk9).
HK1243075A1 (zh) 使前蛋白轉化酶枯草溶菌素/ kexin 9型(pcsk9)減少的方法
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
EP2968266A4 (en) KEXINE ANTI-PROPERTY CONVERTASE CONVERTASE COMPOUNDS TYPE 9 (ANTI-PCSK9) AND METHODS OF USING THE SAME FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
ZA201409210B (en) Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
MX2019006284A (es) Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
MX2017003624A (es) Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
IL266066A (en) Methods for preventing cardiovascular events by reducing the protein proprotein convertase subtilisin kexin 9
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
MY168961A (en) Antibodies to pcsk9 and uses thereof
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MY179341A (en) Method for producing l-amino acids using an alkaliphilic bacteria
EA201792503A1 (ru) Соль (s)-kck s-кетамина, соль (r)-kck s-кетамина и способы получения s-кетамина
SG10201907699YA (en) Substituted pyrazole compounds as serine protease inhibitors
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
MX2017011879A (es) Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
HK1257102A1 (zh) 苯基哌嗪前蛋白轉化酶枯草桿菌蛋白酶/kexin9型(pcsk9)調節劑及其應用
EP3182971A4 (en) Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
EA201792610A1 (ru) Способ лечения неврологического заболевания
IL283374A (en) Cyclic tetramer compounds as (pcsk9) type 9 subtilisin/kexin convertase protein inhibitors for the treatment of metabolic disorders
MX2017008755A (es) Analogos de calcitonina para tratar enfermedades y trastornos.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors